Figure 3. Trial Sample Sizes (1-5)
• A further comparison of the enrolled patient populations indicates that:
• There is a wide variation in sample sizes between trials.
• The LEV-RCT and PER-RCT are the largest and have twice the sample size of the TPM-RCT ( Figure 3 ).
Table 3. Age and Gender Distributions
• Where reported, the mean age at epilepsy onset, mean duration of epilepsy, and mean age at trial enrollment were similar (Table 3 ).
• In age group comparisons that roughly divided patients into pre-adolescent and adolescent / adult age groups, the age distributions reflected the differences in the minimum age limits (Table  3 ).
• There were lower numbers of patients in the pre-adolescent age groups for the LTG-XR-RCT and PER-RCT as they have higher minimum age limits.
• The gender distribution was similar overall. The PER-RCT had slightly more females (Table 3 ).
Figure 4. Median Baseline PGTCS Frequency per 28 Days
• The median baseline PGTCS frequency was similar between trials with the exception of the TPM-RCT which had twice the number of PGTC seizures as other trial populations (Figure 4 ).
Table 4. Baseline Distribution of Seizures Types
• The distribution of baseline seizure types is similar with the exception of the TPM-RCT where 24% of patients had tonic seizures (Table 4 ). • Where reported, the total number of AEDs at baseline was similar between LTG-RCT and LEV-RCT ( Figure 5 ).
• The TPM-RCT and PER-RCT reported the highest number of patients with 3 or more AEDs at baseline ( Figure 5 ).
• Given that inclusion criteria for the TPM-RCT limited the baseline AEDs to a maximum of 2, the report of 26% of patients with 3 or more AEDs may be a result of including rescue medications in the count.
• The count for the PER-RCT does not include rescue medications ( Figure 5 ).
OBJECTIVES
• The objective of this review is to the compare trials of the four anti-epileptic drugs (AEDs) approved specifically for the adjunctive treatment of primary generalized tonic-clonic seizures (PGTCS): TPM, LTG, LEV, LTG-XR, PER.
METHODS

Primary Data Search
• A systematic literature review was conducted to identify randomized controlled trials for anti-epileptic drugs approved for the adjunctive treatment of primary generalized tonic-clonic seizures (PGTCS) in primarily adult populations.
• The methods outlined comply with those published by the Cochrane Collaboration [11] and the UK's National Institute for Health and Clinical Excellence (NICE) [12] .
• The following databases were searched through OVID search platform: EMBASE, MEDLINE, Cochrane Library • Publications were reviewed in a two-step process (abstract review and then full text review) to determine whether they should be included for data extraction. 
PICOS Statement
Inclusion Criteria
RESULTS
• Five trials were identified [Figure 1], one each for: topiramate (TPM-RCT) [1], lamotrigine (LTG-RCT) [2], levetiracetam (LEV-RCT) [3], lamotrigine-XR (LTG-XR-RCT) [4]
, and perampanel (PER-RCT) [5] .
Figure 1. PRISMA Flow Diagram
• All trials were placebo-controlled where the placebo arm continued their baseline AEDs throughout the trial.
• All trials were parallel arm trials, not crossovers.
• Target maintenance doses were:
• TPM (175, 225 or 400 mg/day (weight adjusted)) [1] ,
• LTG (150-500 mg/day depending on age and baseline AEDs) [2] ,
• LEV (3,000 mg/day for adults; 60 mg/kg/day for children) [3] ,
• LTG-XR (200-500 mg/day depending on age and baseline AEDs) [4] ,
• PER (8 mg/day) [5] .
Table 1. Trial Design Summary [1-5]
• Study designs were similar with the exception of ( Table  1 ):
• The PER-RCT which allowed for 1-3 AEDs at baseline while the rest of the trials had a maximum of 2
• The LTG-XR-RCT and PER-RCT which had higher minimum ages, most likely due to the availability of pediatric doses at the time of trial conduct
• The LEV-RCT and PER-RCT which had shorter titration periods
• The LEV-RCT which had the longest maintenance period
Figure 2. Timeline of Trial Enrollment Periods [6-10]
• A comparison of enrollment periods shows that ( Figure 2 ):
• LTG-RCT, LEV-RCT, and LTG-XR-RCT trials had overlapping enrollment periods.
• TPM-RCT is separated by 1 year from the next trial, LTG-RCT.
• PER-RCT is separated by more than 3 years from the closest trial in time, LTG-XR-RCT. • A comparison of the baseline AED composition of these trials illustrates changes in the SOC for PGTCS over time (Table 2 ).
• Drugs approved specifically for PGTCS have generally increased over time (LTG, LEV) with the exception of TPM which as stayed relatively stable. Zonisamide also appears to have increased over time.
• Drugs approved for broader indications (that include PGTCS) have decreased over time:
• Carbamazepine and phenytoin which are approved for generalized tonic-clonic seizures (mix of primary and secondarily generalized)
• Phenobarbital which is approved for all seizures except absence
LIMITATIONS
• Not all data were reported for each trial.
• Some data were reported without sufficient clarifications to determine comparability: LTG-RCT reported baseline PGTCS frequency per month without clarification whether it was 28 or 30-31 days and TPM-RCT reported a large number of patients with 3 or more AEDs at baseline when the inclusion criteria limited this to a maximum of 2. There was no additional information to determine if rescue medications were included in the count.
CONCLUSIONS
• The results overall indicate that the trial designs have remained similar over time.
• The latest trial, the PER-RCT, enrolls patients more than 3 years after the last trial (LTG-XR-RCT) and reasonably allows for up to 3 AEDs at baseline.
• An evaluation of the baseline AEDs in these trials indicates that the SOC has evolved with the approval of new PGTCS drugs in a way which favors drugs that are specifically approved for PGTCS with the exception of TPM which has stayed stable over time. Importantly, drugs approved for broader indications which include PGTCS have decreased overall. This may be due to the influence of guidelines that have warned that carbamazepine and phenytoin may exacerbate seizures.
• International League Against Epilepsy Guidelines state with regard to adults with generalized-onset tonic-clonic seizures: "Class IV evidence suggests that CBZ and PHT may precipitate or aggravate generalized-onset tonic-clonic seizures." [14] • United Kingdom National Institute for Health and Care Excellence states with regard to the adjunctive treatment in children, young people and adults with GTC seizures: "If there are absence or myoclonic seizures, or if JME is suspected, do not offer carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine, or vigabatrin." [15] • Further comparisons of the trial populations indicate that the TPM-RCT population may be different from the other trial populations as the baseline PGTCS frequency was much higher and there were a higher number of patients with tonic seizures at baseline.
